AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible TabletsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020A Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIVView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Targeting Nuclear Receptors to Prevent Cobicistat HepatotoxicityView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Impact of the Hepatitis B Virus (HBV) Capsid Inhibitor, AB-506, on the Single Dose Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020In Utero Exposure to Antiretroviral Drugs and Pregnancy Outcomes: A Secondary Analysis of the ANRS Pharmacovigilance Database From the ANRS-Sponsored HIV Research StudiesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Systematic Review and Meta-Analysis of Adverse Perinatal Outcomes Associated With Prenatal Exposure to Protease Inhibitor Combination in Pregnant Women With HIV InfectionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Tacrolimus and Sirolimus Doses in an HIV-Infected, Kidney-Recipient, Patient Requiring a Cobicistat-Based Antiretroviral RegimenView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Dolutegravir (DTG) Plasma Concentrations Under Different Combinations Regimens for ART- Pre-Treated Adults Living With HIVView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Pharmacokinetics, Safety, and Tolerability of Dolutegravir + Rilpivirine (JULUCA) in Healthy Japanese AdultsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Evaluation of Relationships Between AB-506 Related ALT Elevations and AB-506 Pharmacokinetics (PK), Metabolite Concentrations and Plasma Bile AcidsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020The Pharmacokinetics (PK) of DOVATO (50 mg Dolutegravir (DTG)/ 300 mg Lamivudine (3TC)) Fixed-Dose Combination in HIV-Infected PatientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020Does Dolutegravir Causes Weight Gain?: A Retrospective Observational Cohort Study From Lusaka, ZambiaView Abstract
